

6. Literatur

Ich möchte mich bei allen entschuldigen, deren Arbeiten aus Platzgründen hier nicht genannt werden konnten.

Alberta, J. A., et al. (2003) Role of the WT1 tumor suppressor in murine hematopoiesis. *Blood* 101: 2570-2574

Algar, E. M., et al. (1996) A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. *Oncogene* 12:1005-14

Armstrong, J. F., et al. (1992): The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. *Mech. Dev.* 40: 85-97

Baird, P. N., Simmons, P. J. (1997) Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. *Exp. Hematol.* 25: 312-320

Barboux, S., et al. (1997) Donor splice-site mutations in WT1 are responsible for Frasier syndrome. *Nat. Genet.* 17: 467-470

Bardeesy, N., Pelletier, J. (1998) Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product. *Nucleic Acids Res.* 26: 1784-1792

Beckwith, J. B., et al. (1990) Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. *Pediatr. Pathol.* 10: 1-36

Bickmore, W. A., et al. (1992) Modulation of DNA binding specificity by alternative splicing of the Wilms tumor wt1 gene transcript. *Science* 257: 235-237

Bonetta, L., et al. (1990) The Wilms' tumor locus on 11p13 defined by multiple CpG island-associated transcripts. *Science* 250: 994-997

Braissant, O., Wahli, W. (1998) A simplified in situ hybridization protocol using non-radioactive labeled probes to detect abundant and rare mRNAs on tissue sections. *Biochemica* 1: 10-16

Bruening, W., et al. (1996) Identification of nuclear localization signals within the zinc fingers of the WT1 tumor suppressor gene product. *FEBS Lett.* 393: 41-47

Bruening, W., Pelletier, J. (1996) A non-AUG translational initiation event generates novel WT1 isoforms. *J. Biol. Chem.* 271: 8646-8654

Buckler, A. J., et al. (1991) Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. *Mol. Cell. Biol.* 11: 1707-1712

Budhram-Mahadeo, V., et al. (1998) POU transcription factors Brn-3a and Brn-3b interact with the estrogen receptor and differentially regulate transcriptional activity via an estrogen response element. *Mol. Cell. Biol.* 18: 1029-1041

Budhram-Mahadeo, V., et al. (1999) The Brn-3b POU family transcription factor represses expression of the BRCA-1 anti-oncogene in breast cancer cells. *Oncogene* 18: 6684-6691

Budhram-Mahadeo, V., et al. (2001) The closely related POU family transcription factors Brn-3a and Brn-3b are expressed in distinct cell types in the testis. *Int. J. Biochem. Cell Biol.* 33: 1024-1039

Call, K. M., et al. (1990) Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. *Cell* 60: 509-520

Caricasole, A., et al. (1996) RNA binding by the Wilms tumor suppressor zinc finger proteins. *Proc. Natl. Acad. Sci. USA* 93: 7562-7566

Carpenter, B., et al. (2004) BASP1 is a transcriptional cosuppressor for the Wilms' tumor suppressor protein WT1. *Mol. Cell. Biol.* 24: 537-549

Chomczynski, P., Sacchi, N. (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* 162: 156-159

Classon, M., Harlow, E. (2002) The retinoblastoma tumour suppressor in development and cancer. *Nat. Rev. Cancer* 2: 910-917

Dalosso, A. R., et al. (2004) Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours. *Hum. Mol. Genet.* 13: 405-415

Dame, C., et al. (2006) Wilms tumor suppressor, Wt1, is a transcriptional activator of the erythropoietin gene. *Blood* 107: 4282-4290

Davies, R. C., et al. (1998) WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. *Genes Dev.* 12: 3217-3225

Davies, J. A., et al. (2004) Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation. *Hum. Mol. Genet.* 13: 235-246

- Dennis, J. H., et al. (2001) The Brn-3b POU family transcription factor regulates the cellular growth, proliferation, and anchorage dependence of MCF7 human breast cancer cells. *Oncogene* 20: 4961-4971
- Dennis, S. L., et al. (2002) Expression and mutation analysis of the Wilms' tumor 1 gene in human neural tumors. *Int. J. Cancer* 97: 713-715
- Dome, J. S., Coppes, M. J. (2002) Recent advances in Wilms tumor genetics. *Curr. Opin. Pediatr.* 14: 5-11
- Donovan, M. J., et al. (1999) Initial differentiation of the metanephric mesenchyme is independent of WT1 and the ureteric bud. *Dev. Genet.* 24: 252-262
- Drager, U. C., Olsen, J. F. (1981): Ganglion cell distribution in the retina of the mouse. *Invest. Ophthalmol. Vis. Sci.* 20: 285-293
- Drummond, I. A., et al. (1994) DNA recognition by splicing variants of the Wilms' tumor suppressor, WT1. *Mol. Cell. Biol.* 14: 3800-3809
- Dyer, M. A., Bremner, R. (2005) The search for the retinoblastoma cell of origin. *Nat. Rev. Cancer* 5: 91-101
- Ellisen, L. W., et al. (2001) The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. *EMBO J.* 20: 1897-909
- Englert, C., et al. (1995a) Truncated WT1 mutants alter the subnuclear localization of the wild-type protein. *Proc. Natl. Acad. Sci. USA* 92: 11960-11964
- Englert, C., et al. (1995b) WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. *EMBO J.* 14: 4662-4675
- English, M. A., Licht, J. D. (1999) Tumor-associated WT1 missense mutants indicate that transcriptional activation by WT1 is critical for growth control. *J. Biol. Chem.* 274: 13258-13263
- Erkman, L., et al. (1996) Role of transcription factors Brn-3.1 and Brn-3.2 in auditory and visual system development. *Nature* 381: 603-606
- Erkman, L., et al. (2000): A POU domain transcription factor-dependent program regulates axon pathfinding in the vertebrate visual system. *Neuron* 28: 779-792
- Fabre, A., et al. (1999) Loss of heterozygosity of the Wilms' tumor suppressor gene (WT1) in in-situ and invasive breast carcinoma. *Hum. Pathol.* 30: 661-665

Freund, C., et al. (1996) Transcription factor genes and the developing eye: a genetic perspective. *Hum. Mol. Genet.* 5: 1471-1488

Gan, L., et al. (1996) POU domain factor Brn-3b is required for the development of a large set of retinal ganglion cells. *Proc. Natl. Acad. Sci. USA* 93: 3920-3925

Gan, L., et al. (1999) POU domain factor Brn-3b is essential for retinal ganglion cell differentiation and survival but not for initial cell fate specification. *Dev. Biol.* 210: 469-480

Gessler, M., et al. (1990) Homozygous deletions in Wilms' tumours of a zinc-finger gene identified by chromosome jumping. *Nature* 343: 774-778

Gessler, M., et al. (1992) The genomic organization and expression of the WT1 gene. *Genomics* 12: 807-813

Guo, G., et al. (2004) WT1 activates a glomerular-specific enhancer identified from the human nephrin gene. *J. Am. Soc. Nephrol.* 15: 3044-3051

Guo, J. K., et al. (2002) WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. *Hum. Mol. Genet.* 11: 651-659

Haber, D. A., et al. (1990) An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. *Cell* 61: 1257-1269

Haber, D. A., et al. (1991) Alternative splicing and genomic structure of the Wilms' tumor gene WT1. *Proc. Natl. Acad. Sci. USA* 88: 9618-9622

Hammes, A., et al. (2001) Two splice variants of the Wilms' tumor WT1 gene have distinct functions during sex determination and nephron formation. *Cell* 106, 319-329

Hastie, N. D. (1994) The genetics of Wilms' tumor: a case of disrupted development. *Annu. Rev. Genet.* 28: 523-558

Hatano, O., et al. (1996) Identical origin of adrenal cortex and gonad revealed by expression profiles of Ad4BP/SF-1. *Genes Cells* 1: 663-671

Herzer, U., et al. (1999) The Wilms tumor suppressor gene wt1 is required for development of the spleen. *Curr. Biol.* 9: 837-840

Huff, V. (1998) Wilms tumor genetics. *Am. J. Med. Genet.* 79: 260-267

Ito, S., et al. (1999) Nephrotic syndrome and end-stage renal disease with WT1 mutation detected at 3 years. *Pediatr. Nephrol.* 13: 790-791

- Jean, D., et al. (1998) Molecular regulators involved in vertebrate eye development. *Mech. Dev.* 76: 3-18
- Jeon, C.-J., et al. (1998) The major cell populations of the mouse retina. *J. Neurosci.* 18: 8936-8946
- Kanato, K., et al. (2005) The Wilms' tumor gene WT1 is a common marker of progenitor cells in fetal liver. *Biochem. Biophys. Res. Commun.* 326:836-843
- Kennedy, D., et al. (1996) An RNA recognition motif in Wilms' tumour protein (WT1) revealed by structural modelling. *Nat. Genet.* 12: 329-332
- Kent, J., et al. (1995) The evolution of WT1 sequence and expression pattern in the vertebrates. *Oncogene* 11: 1781-1792
- King-Underwood, L., et al. (2005) Wt1 is not essential for hematopoiesis in the mouse. *Leuk. Res.* 29: 803-812
- Kinzler, K. W., Vogelstein, B. (1997) Gatekeepers and Caretakers. *Nature* 386: 761-763
- Klamt, B., et al. (1998) Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1 +/-KTS splice isoforms. *Hum. Mol. Genet.* 7: 709-714
- Knudson, A. G. (1971) Mutation and cancer: statistical study of retinoblastoma. *Proc. Natl. Acad. Sci. USA* 68: 820-823
- Kobayashi, N., et al. (2004) Process formation of the renal glomerular podocyte: Is there common molecular machinery for processes of podocytes and neurons? *Anat. Sci. Int.* 79 : 1-10
- Kreidberg, J. A., et al. (1993): WT-1 is required for early kidney development. *Cell* 74: 679-691
- Kudoh, T., et al. (1995) G1 phase arrest induced by Wilms tumor protein WT1 is abrogated by cyclin/CDK complexes. *Proc. Natl. Acad. Sci. USA* 92: 4517-4521
- Ladomery, M. R., et al. (1999) Presence of WT1, the Wilm's tumor suppressor gene product, in nuclear poly(A)⁺ ribonucleoprotein. *J. Biol. Chem.* 274: 36520-36526
- Laity, J. H., et al. (2000a) Alternative splicing of Wilms' tumor suppressor protein modulates DNA binding activity through isoform-specific DNA-induced conformation changes. *Biochemistry* 39: 5341-5348
- Laity, J. H., et al. (2000b) Molecular basis for modulation of biological function by alternate splicing of the Wilms' tumor suppressor protein. *Proc. Natl. Acad. Sci. USA* 97: 11932-11935

- Larsson, S. H., et al. (1995) Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. *Cell* 81: 391-401
- Lee, S. B., et al. (1999) The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. *Cell* 98: 663-673
- Lee, S. B., Haber, D. A. (2001) Wilms tumor and the WT1 gene. *Exp. Cell Res.* 264: 74-99
- Little, M. H., et al. (1993) Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion. *Hum. Mol. Genet.* 2: 259-264
- Little, M., Wells, C. (1997) A clinical overview of WT1 gene mutation. *Hum. Mutat.* 9: 209-225
- Little, N. A., et al. (2000) Identification of WTAP, a novel Wilms' tumour 1-associating protein. *Hum. Mol. Genet.* 9: 2231-2239
- Liu, W., et al. (2001) The Ath5 proneural genes function upstream of Brn3 POU domain transcription factor genes to promote retinal ganglion cell development. *Proc. Natl. Acad. Sci. USA* 98: 1649-1654
- Livesey, F. J., Cepko, C. L. (2001) Vertebrate neural cell-fate determination: lessons from the retina. *Nature Rev. Neurosci.* 2: 109-118
- Loeb, D. M., et al. (2001) Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. *Cancer Res.* 61: 921-925
- Lovell, M. A., et al. (2003) Wilms' tumor suppressor (WT1) is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer's disease. *Brain Res.* 983:84-96
- Luo, X., et al. (1994) A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. *Cell* 77: 481-490
- Madden, S. L., et al. (1993) A structure-function analysis of transcriptional repression mediated by the WT1, Wilms' tumor suppressor protein. *Oncogene* 8: 1713-1720
- Maheswaran, S., et al. (1995) The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. *Genes Dev.* 9: 2143-2156
- Martin, S. E., et al. (2005) Identification of an N-terminal transcriptional activation domain within Brn3b/POU4f2. *Differentiation* 73: 18-27
- Mayo, M. W., et al. (1999) WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. *EMBO J.* 18: 3990-4003

- Moffett, P., et al. (1995) Antagonism of WT1 activity by protein self-association. *Proc. Natl. Acad. Sci. USA* 92: 11105-11109
- Moore, A. W., et al. (1998) YAC transgenic analysis reveals Wilms' Tumour 1 gene activity in the proliferating coelomic epithelium, developing diaphragm and limb. *Mech. Dev.* 79: 169-184
- Moore, A. W., et al. (1999) YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis. *Development* 126: 1845-1857
- Morris, J. F., et al. (1991) Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus. *Oncogene* 6: 2339-2348
- Mrowka, C., Schedl, A. (2000) Wilms' tumor suppressor gene WT1: from structure to renal pathophysiologic feature. *J. Am. Soc. Nephrol.* 11: S106-S115
- Mundlos, S., et al. (1993) : Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues. *Development* 119: 1329-1341
- Nakagama, H., et al. (1995) Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product. *Mol. Cell. Biol.* 15: 1489-1498
- Nathanson, K. L., et al. (2001) Breast cancer genetics: What we know and what we need. *Nat. Med.* 7: 552-556)
- Natoli, T. A., et al. (2002a) A mammal-specific exon of WT1 is not required for development of fertility. *Mol. Cell. Biol.* 22: 4433-4438
- Natoli, T. A., et al. (2002b) A mutant form of the Wilms' tumor suppressor gene WT1 observed in Denys-Drash syndrome interferes with glomerular capillary development. *J. Am. Soc. Nephrol.* 13: 2058-2067
- Natoli, T. A., et al. (2004) Wt1 functions in the development of germ cells in addition to somatic cell lineages of the testis. *Dev. Biol.* 268: 429-440
- Pan, L., et al. (2005) Functional equivalence of Brn3 POU-domain transcription factors in mouse retinal neurogenesis. *Development* 132: 703-712
- Park, S., et al. (1993): The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in human mesothelioma. *Nat. Genet.* 4: 415-420
- Patek, C. E., et al. (1999) A zinc finger truncation of murine WT1 results in the characteristic urogenital abnormalities of Denys-Drash syndrome. *Proc. Natl. Acad. Sci. USA* 96: 2931-2936

Pavenstädt, H. (2000) Roles of the podocyte in glomerular function. *Am. J. Physiol. Renal Physiol.* 278: F173-F179

Pelletier, J., et al. (1991a) Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. *Cell* 67: 437-447

Pelletier, J., et al. (1991b): Expression of the Wilms' tumor gene WT1 in the murine urogenital system. *Genes Dev.* 5: 1345-1356

Perez-Pomares, J. M., et al. (2002) Experimental studies on the spatiotemporal expression of WT1 and RALDH2 in the embryonic avian heart: a model for the regulation of myocardial and valvuloseptal development by epicardially derived cells (EPDCs). *Dev. Biol.* 247:307-326

Perry, V.H., et al. (1983) Postnatal changes in retinal ganglion cell and optic axon populations in the pigmented rat. *J. Comp. Neurol.* 219: 356-368

Plaza, S., et al. (1999) Evidence that POU factor Brn-3b regulates expression of Pax-6 in neuroretina cells. *J. Neurobiol.* 41: 349-358

Prada, C., et al. (1991) Spatial and temporal patterns of neurogenesis in the chick retina. *Eur. J. Neurosci.* 3, 559-569

Pritchard-Jones, K., et al. (1990): The candidate Wilms' tumour gene is involved in genitourinary development. *Nature* 346: 194-197

Rackley, R. R., et al. (1993) : Expression of the Wilms' tumor suppressor gene WT1 during mouse embryogenesis. *Cell Growth Differ.* 4: 1023-1031

Rao, M. K., et al. (2006) Tissue-specific RNAi reveals that WT1 expression in nurse cells controls germ cell survival and spermatogenesis. *Genes Dev.* 20: 147-152

Rauscher, F. J. 3rd, et al. (1990) Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. *Science* 250: 1259-1262

Reddy, J. C., et al. (1995a) WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins. *J. Biol. Chem.* 270: 10878-10884

Reddy, J. C., et al. (1995b) The transcriptional effect of WT1 is modulated by choice of expression vector. *J. Biol. Chem.* 270: 29976-29982

Reizner, N., et al. (2005) The WT1 Wilms' tumor suppressor gene product interacts with estrogen receptor- α and regulates IGF-I receptor gene transcription in breast cancer cells. *J. Mol. Endocrinol.* 35: 135-144

- Renshaw, J., et al. (1997) Differential splicing of exon 5 of the Wilms' tumour (WT1) gene. *Genes Chromosomes Cancer* 19: 256-266
- Richard, D. J., et al. (2001) Par4 is a coactivator for a splice isoform-specific transcriptional activation domain in WT1. *Genes Dev.* 15: 328-339
- Rivera, M. N, Haber, D. A. (2005) Wilms' tumour: connecting tumorigenesis and organ development in the kidney. *Nat. Rev. Cancer* 5: 699-712
- Ryan, A. K., Rosenfeld, M. G. (1997) POU domain family values: flexibility, partnership and developmental codes. *Genes Dev* 11: 1207-1225
- Sakamoto, Y., et al. (1997) Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain. *Oncogene* 15: 2001-2012
- Saxen, L. (1987) Organogenesis of the kidney. In: Barlow P. W. et al. (eds.) *Developmental and Cell Biology Series 19*, Cambridge University Press, Cambridge, UK
- Scharnhorst, V., et al. (1997) Differential regulation of the Wilms' tumor gene WT1 during differentiation of embryonal carcinoma and embryonic stem cells. *Cell Growth Differ.* 8: 133-143
- Scharnhorst, V., et al. (1999) Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties. *J. Biol. Chem.* 274: 23456-23462
- Scharnhorst, V., et al. (2001) WT1 proteins: functions in growth and differentiation. *Gene* 273: 141-161
- Sharma, P. M., et al. (1992) Molecular cloning of rat Wilms' tumor complementary DNA and a study of messenger RNA expression in the urogenital system and the brain. *Cancer Res.* 52: 6407-6412
- Sharma, P. M., et al. (1994) RNA editing in the Wilms' tumor susceptibility gene, WT1. *Genes Dev.* 8: 720-731
- Sidman, R. L. (1961) Histogenesis of Mouse Retina Studied with Thymidine-H³. In: Smelser GK (Ed.): *The Structure of the Eye*. Academic Press, New York, S. 487-505
- Silberstein, G. B., et al. (1997) Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer. *Proc. Natl. Acad. Sci. USA* 94: 8132-8137

- Smith, M. D., et al. (1997) Inhibition of neuronal process outgrowth and neuronal specific gene activation by the Brn-3b transcription factor. *J. Biol. Chem.* 272: 1382-1388
- Smolen, G. A., et al. (2004) SUMO-1 modification of the Wilms' tumor suppressor WT1. *Cancer Res.* 64: 7846-7851
- Srichai, M. B., et al. (2004) A WT1 co-regulator controls podocyte phenotype by shuttling between adhesion structures and nucleus. *J. Biol. Chem.* 279: 14398-14408
- Theil, T., et al. (1993) Mouse Brn-3 family of POU transcription factors: a new amino terminal domain is crucial for the oncogenic activity of Brn-3a. *Nucleic Acids Res.* 21: 5921-5929
- Ton, C. C. T., et al. (1991) Positional cloning and characterization of a paired box- and homeobox-containing gene from the aniridia region. *Cell* 67:1059-1074
- Trieu, M., et al. (1999) Autoregulatory sequences are revealed by complex stability screening of the mouse brn-3.0 locus. *J. Neurosci.* 19: 6549-6558
- Trieu, M., et al. (2003) Direct autoregulation and gene dosage compensation by POU-domain transcription factor Brn3a. *Development* 130: 111-121
- Tuna, M., et al. (2005) HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. *Oncogene* 24: 1648-1652
- Turner, E. E., et al. (1994) Brn-3.2: A Brn-3-related transcription factor with distinctive central nervous system expression and regulation by retinoic acid. *Neuron* 12: 205-218
- Vajjhala, P. R., et al. (2003) The Wilms' tumour suppressor protein, WT1, undergoes CRM1-independent nucleocytoplasmic shuttling. *FEBS Lett.* 554: 143-148
- Wagner, K. D., et al. (2001) Activation of vitamin D receptor by the Wilms' tumor gene product mediates apoptosis of renal cells. *J. Am. Soc. Nephrol.* 12: 1188-1196
- Wagner, N., et al. (2002) The Wilms' tumor suppressor Wt1 is associated with the differentiation of retinoblastoma cells. *Cell Growth Differ.* 13: 297-305
- Wagner, N., et al. (2004) The major podocyte protein nephrin is transcriptionally activated by the Wilms' tumor suppressor WT1. *J. Am. Soc. Nephrol.* 15: 3044-3051
- Wagner, N., et al. (2005) A splice variant of the Wilms' tumour suppressor Wt1 is required for normal development of the olfactory system. *Development* 132: 1327-1336

- Wang, S. W., et al. (2000): Abnormal polarization and axon outgrowth in retinal ganglion cells lacking the POU-domain transcription factor Brn-3b. *Mol. Cell. Neurosci.* 16: 141-156
- Wang, S. W., et al. (2002): Brn3b/Brn3c double knockout mice reveal an unsuspected role for Brn3c in retinal ganglion cell axon outgrowth. *Development* 129: 467-477
- Wang, Z. Y., et al. (1993) A second transcriptionally active DNA-binding site for the Wilms tumor gene product, WT1. *Proc. Natl. Acad. Sci. USA* 90: 8896-8900
- Wang, Z. Y., et al. (1995a) Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways. *Oncogene* 10: 415-422
- Wang, Z. Y., et al. (1995b) WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein. *Oncogene* 10: 1243-1247
- Wilhelm, D., Englert, C. (2002) The Wilms tumor suppressor WT1 regulates early gonad development by activation of Sfl. *Genes Dev.* 16: 1839-1851
- Wilms, M. (1899) Die Mischgeschwülste der Niere. Arthur Georgie, Leipzig, S. 1-90
- Xiang, M. (1998) Requirement for Brn-3b in early differentiation of postmitotic retinal ganglion cell precursors. *Dev. Biol.* 1997: 155-169
- Xiang, M., et al. (1993) Brn-3b: a POU domain gene expressed in a subset of retinal ganglion cells. *Neuron* 11: 689-701
- Xiang, M., et al. (1995) The Brn-3 family of POU-domain factors: primary structure, binding specificity and expression in subsets of retinal ganglion cells and somatosensory neurons. *J. Neurosci.* 15: 4762-4785
- Yamagami, T., et al. (1998) Suppression of Wilms' tumor gene (WT1) expression induces G2/M arrest in leukemic cells. *Leuk. Res.* 22:383-4
- Ye, Y., et al. (1996) Regulation of WT1 by phosphorylation: Inhibition of DNA binding, alteration of transcriptional activity and cellular translocation. *EMBO J.* 15: 5606-5615
- Young, R. W. (1984) Cell death during differentiation of the retina in the mouse. *J. Comp. Neurol.* 229: 362-373
- Young, R. W. (1985) Cell differentiation in the retina of the mouse. *Anat. Rec.* 212: 199-205

Zapata-Benavides, P., et al. (2002) Downregulation of Wilms' tumor protein inhibits breast cancer proliferation. *Biochem. Biophys. Res. Commun.* 295: 784-790

Zhou, J., et al. (1993) Wilms' tumor (WT1) gene expression in rat decidual differentiation. *Differentiation* 54: 109-114